Raynaud phenomenon
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
severe secondary RP: critical ischemia with digital ulcers or threatened digital loss
prostacyclin and/or phosphodiesterase-5 inhibitor
Prostacyclins (particularly iloprost) are used to treat complications of severe secondary RP, such as threatened digital loss due to ischemia and digital ulcers.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23. https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661 http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com [33]Huisstede BM, Hoogvliet P, Paulis WD, et al. Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review. Arch Phys Med Rehabil. 2011 Jul;92(7):1166-80. http://www.ncbi.nlm.nih.gov/pubmed/21704799?tool=bestpractice.com These drugs can be effective for several months after treatment. Treatment with prostacyclins alone has been shown to decrease the frequency/severity of attacks and heals/prevents digital ulcers.[41]Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug;76(8):1327-39. https://ard.bmj.com/content/76/8/1327.long http://www.ncbi.nlm.nih.gov/pubmed/27941129?tool=bestpractice.com [63]Ingegnoli F, Schioppo T, Allanore Y, et al. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus. Semin Arthritis Rheum. 2019 Feb;48(4):686-93. http://www.ncbi.nlm.nih.gov/pubmed/29706243?tool=bestpractice.com Intravenous iloprost is generally considered to be the first-line prostacyclin; however, the intravenous formulation may not be available in some countries, and the inhaled formulation is generally not recommended for this indication. Therefore, intravenous epoprostenol can be used as an alternative to intravenous iloprost.
Phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil, vardenafil) can be used for patients with moderate to severe secondary RP when calcium-channel blockers have failed or are not tolerated.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23. https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661 http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com [41]Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug;76(8):1327-39. https://ard.bmj.com/content/76/8/1327.long http://www.ncbi.nlm.nih.gov/pubmed/27941129?tool=bestpractice.com [55]Roustit M, Blaise S, Allanore Y, et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013 Oct;72(10):1696-9. http://www.ncbi.nlm.nih.gov/pubmed/23426043?tool=bestpractice.com [56]Fernández-Codina A, Walker KM, Pope JE, et al. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018 Nov;70(11):1820-8. https://onlinelibrary.wiley.com/doi/full/10.1002/art.40560 http://www.ncbi.nlm.nih.gov/pubmed/29781586?tool=bestpractice.com Trials have shown a positive benefit with sildenafil in RP.[57]Herrick AL, van den Hoogen F, Gabrielli A, et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum. 2011 Mar;63(3):775-82. https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.30195 http://www.ncbi.nlm.nih.gov/pubmed/21360507?tool=bestpractice.com [58]Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005 Nov 8;112(19):2980-5. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.104.523324 http://www.ncbi.nlm.nih.gov/pubmed/16275885?tool=bestpractice.com Longer-acting PDE-5 inhibitors such as tadalafil are also used. Although dosing for tadalafil is more convenient, it has shown positive findings in RP only in a small crossover study, but not in combination with prostacyclins.[59]Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford). 2010 Dec;49(12):2420-8. https://academic.oup.com/rheumatology/article/49/12/2420/1791021?login=false http://www.ncbi.nlm.nih.gov/pubmed/20837499?tool=bestpractice.com A trial of vardenafil versus placebo in RP has shown that vardenafil is associated with a reduction in frequency and duration of RP attacks and Raynaud's Condition Score (RCS).[60]Caglayan E, Axmann S, Hellmich M, et al. Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med. 2012 Aug 13;172(15):1182-4. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1188038 http://www.ncbi.nlm.nih.gov/pubmed/22710940?tool=bestpractice.com A 2023 Cochrane systematic review reported that PDE-5 inhibitors may reduce the frequency and duration of RP attacks.[62]Maltez N, Maxwell LJ, Rirash F, et al. Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon. Cochrane Database Syst Rev. 2023 Nov 6;11(11):CD014089. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014089/full http://www.ncbi.nlm.nih.gov/pubmed/37929840?tool=bestpractice.com
A prostacyclin would not normally be combined with a PDE-5 inhibitor due to the potential for drug interactions. Also, combining a prostacyclin and PDE-5 inhibitor can cause significant hypotension. However, if RP is sufficently severe to warrant prostanoid treatment, the patient would likely be referred to an expert center where a combination treatment may be considered.
Primary options
epoprostenol: 2 nanograms/kg/min intravenous infusion initially, increase by 2 nanograms/kg/min every 15 mins or longer according to response
More epoprostenolUse permanent central line. Dose escalation dependent on tolerability.
OR
sildenafil: 12.5 mg orally twice daily initially, increase according to response, maximum 100 mg/day (given in 2-3 divided doses)
OR
tadalafil: 5-40 mg orally once daily
OR
vardenafil: consult specialist for guidance on dose
lifestyle measures
Treatment recommended for ALL patients in selected patient group
Lifestyle measures should also be considered alongside treatment in people with secondary RP who have progressed to digital ulceration. These include keeping warm and avoiding damp: for instance, by wearing gloves or using hand warmers. Patients should be advised to quit smoking and avoid drugs known to exacerbate RP (e.g., beta-blockers, ergotamine, clonidine, cyclosporine, caffeine, cocaine, amphetamines). Avoiding injury to digits and exposure to vibration, as well as minimizing stress, are also recommended. Vasoconstrictor drugs should be discontinued where possible.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23. https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661 http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com [31]Parodis I, Gomez A, Tsoi A, et al. Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. RMD Open. 2023 Aug;9(3):e003297. https://rmdopen.bmj.com/content/9/3/e003297.long http://www.ncbi.nlm.nih.gov/pubmed/37532469?tool=bestpractice.com Patients should also be advised to moisturize the skin around ulcers, avoid contact with cleaning agents, avoid manipulation of ulcers, wear protective gloves, and promote circulation through exercise.[32]Stöcker JK, Schouffoer AA, Spierings J, et al. Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis. Rheumatology (Oxford). 2022 Apr 11;61(4):1476-86. https://academic.oup.com/rheumatology/article/61/4/1476/6321467?login=false http://www.ncbi.nlm.nih.gov/pubmed/34260723?tool=bestpractice.com If dexterity limitations are reported, patients should undergo occupational therapy assessment for aids (e.g., key holders).
treatment of underlying condition
Treatment recommended for ALL patients in selected patient group
Treatment for the underlying condition that has resulted in secondary RP should be instigated after appropriate specialist consultation.
atorvastatin
Treatment recommended for SOME patients in selected patient group
Atorvastatin has been found to decrease new ulcer formation in patients with secondary RP and may be used in patients with past or present ulcers, but is not indicated for the prevention of digital ulcers.[35]Hughes M, Ong VH, Anderson ME, et al. Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology (Oxford). 2015 Nov;54(11):2015-24. http://www.ncbi.nlm.nih.gov/pubmed/26116156?tool=bestpractice.com [66]Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol. 2008 Sep;35(9):1801-8. https://www.jrheum.org/content/35/9/1801.long http://www.ncbi.nlm.nih.gov/pubmed/18709692?tool=bestpractice.com
Primary options
atorvastatin: 40 mg orally once daily
analgesia
Treatment recommended for SOME patients in selected patient group
Pain relief is an important component of symptom management. Vasodilators treat the pain of RP if they are effective in reducing the frequency, severity, or duration of attacks. However, analgesics may be required to treat pain from severe or prolonged ischemia or complications such as gangrene or digital ulcers.
Local pain management algorithms should be followed, and treatment should be tailored to medical history and any relative/absolute contraindications. Simple analgesics such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) may be sufficient. Short- or long-acting opioids may be required. Digital ulcers may be very painful, and codeine or oxycodone may be indicated. Rarely, transdermal fentanyl is used if other opioids are not effective or not tolerated, typically for patients with gangrene or osteomyelitis.
Primary options
acetaminophen: 325-1000 mg orally/rectally every 4-6 hours when required, maximum 4000 mg/day
OR
ibuprofen: 300-400 mg orally every 4-6 hours when required, maximum 2400 mg/day
OR
naproxen: 250-500 mg orally twice daily when required, maximum 1250 mg/day
OR
diclofenac potassium: 50 mg orally (immediate-release) twice or three times daily when required
OR
diclofenac sodium: 100 mg orally (extended-release) once daily when required
Secondary options
codeine sulfate: 15-60 mg orally every 4-6 hours when required, maximum 360 mg/day
OR
oxycodone: 5-10 mg orally (immediate-release) every 4-6 hours when required; 10 mg orally (extended-release) every 12 hours when required
Tertiary options
fentanyl transdermal: 12.5 micrograms/hour patch applied every 72 hours, increase to 25 micrograms/hour patch applied every 72 hours if required
aspirin
Treatment recommended for SOME patients in selected patient group
Aspirin may be beneficial in helping prevent microthrombi formation.
Primary options
aspirin: 81 mg orally once daily
surgical debridement
Treatment recommended for SOME patients in selected patient group
If there is a large fingertip ulcer, debridement by a surgeon may be necessary to remove necrotic tissue and/or infection and to promote healing.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23. https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661 http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com If gangrene has progressed in spite of treatment, amputation of the digit may be required.
systemic antibiotics
Treatment recommended for SOME patients in selected patient group
Antibiotics should be given when ulcers are infected. Infections are often due to Staphylococcus aureus or Pseudomonas aeruginosa, but can also be caused by Escherichia coli, Enterococcus faecalis, Streptococcus epidermidis, or Bacillus morganii.[73]Giuggioli D, Magnani L, Spinella A, et al. Infections of scleroderma digital ulcers: a single center cohort retrospective study. Dermatol Reports. 2021 Nov 17;13(3):9075. https://www.pagepress.org/journals/index.php/dr/article/view/9075 http://www.ncbi.nlm.nih.gov/pubmed/35003566?tool=bestpractice.com If there is frank purulence, it is advisable to take a swab for culture and sensitivities prior to starting antibiotics, and to tailor treatment based on swab sensitivities and severity of infection. Examples of antibiotic options may include cloxacillin, cephalexin, or erythromycin. However, you should consult your local protocols for guidance.
If infection is not resolved after 7 days of treatment (e.g., continued discolored purulence), treat for another 3 to 7 days.
If osteomyelitis is suspected, seek specialist advice from a microbiologist. See Osteomyelitis.
Primary options
cephalexin: 500 mg orally four times daily
Secondary options
erythromycin base: 250-500 mg orally four times daily
topical antibacterial ointment
Treatment recommended for SOME patients in selected patient group
Topical antibacterials can be used if there is no evidence of a serious infection, but these may be working as a barrier and lubricant more than an antibacterial.
Primary options
mupirocin topical: apply ointment thinly to ulcer twice daily
OR
bacitracin/polymyxin B topical: apply ointment thinly to ulcer twice daily
bosentan
Treatment recommended for SOME patients in selected patient group
Can be used to help prevent formation of systemic sclerosis-related digital ulcers.[67]Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004 Dec;50(12):3985-93. http://onlinelibrary.wiley.com/doi/10.1002/art.20676/full http://www.ncbi.nlm.nih.gov/pubmed/15593188?tool=bestpractice.com [68]Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011 Jan;70(1):32-8. https://ard.bmj.com/content/70/1/32.long http://www.ncbi.nlm.nih.gov/pubmed/20805294?tool=bestpractice.com [69]Hosseinbalam M, Nouri R, Farajzadegan Z, et al. Effectiveness of bosentan in the treatment of systemic sclerosis-related digital ulcers: systematic review and meta-analysis. J Res Med Sci. 2023 Jan 31:28:3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039099 http://www.ncbi.nlm.nih.gov/pubmed/36974107?tool=bestpractice.com It has been found to reduce the incidence of new ulcers by 30% to 50%.[68]Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011 Jan;70(1):32-8. https://ard.bmj.com/content/70/1/32.long http://www.ncbi.nlm.nih.gov/pubmed/20805294?tool=bestpractice.com However, it is not superior to usual care in healing current ulcers.
Liver function tests need to be checked monthly during treatment, and the duration of treatment required for prevention of digital ulcers is unknown but may be indefinitely.[67]Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004 Dec;50(12):3985-93. http://onlinelibrary.wiley.com/doi/10.1002/art.20676/full http://www.ncbi.nlm.nih.gov/pubmed/15593188?tool=bestpractice.com [70]Varga J. New hope for systemic sclerosis patients with digital ulcers. Curr Rheumatol Rep. 2005 Apr;7(2):127-8. http://www.ncbi.nlm.nih.gov/pubmed/15760591?tool=bestpractice.com [71]Seibold JR, Matucci-Cerinic M, Denton CP, et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. Ann Rheum Dis. 2006;65(suppl II):90. This use is off-label in the US.
Primary options
bosentan: 62.5 mg orally twice daily for 1 month, followed by 125 mg orally twice daily thereafter
More bosentanRestricted distribution in US.
surgical sympathectomy
Surgical sympathectomy may be effective in the treatment of severe RP that has failed pharmacologic treatment.[6]Casanegra AI, Shepherd RF. Raynaud phenomenon and other vasospastic disorders. Cardiol Clin. 2021 Nov;39(4):583-99 http://www.ncbi.nlm.nih.gov/pubmed/34686269?tool=bestpractice.com [35]Hughes M, Ong VH, Anderson ME, et al. Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology (Oxford). 2015 Nov;54(11):2015-24. http://www.ncbi.nlm.nih.gov/pubmed/26116156?tool=bestpractice.com Techniques available include stellate ganglion or lumbar sympathetic blocks, proximal cervical sympathectomies via endoscopic surgery, and selective palmar and/or digital sympathectomies.[74]Wasserman A, Brahn E. Systemic sclerosis: bilateral improvement of Raynaud's phenomenon with unilateral digital sympathectomy. Semin Arthritis Rheum. 2010 Oct;40(2):137-46. http://www.ncbi.nlm.nih.gov/pubmed/19878974?tool=bestpractice.com Such techniques may not be available in all centers. A 2022 study reported pain relief with prevention of major amputation in 68 children with rheumatologic disorders presenting with RP after sympathetic blocks (including stellate ganglion blocks).[75]Punj J, Garg H, Gomez G, et al. Sympathetic blocks for Raynaud's phenomena in pediatric rheumatological disorders. Pain Med. 2022 Jul 1;23(7):1211-6. https://academic.oup.com/painmedicine/article/23/7/1211/6522132?login=false http://www.ncbi.nlm.nih.gov/pubmed/35135008?tool=bestpractice.com In one retrospective study of 17 patients with systemic sclerosis, localized palmar or digital sympathectomy improved pain and ulcer healing.[76]Momeni A, Sorice SC, Valenzuela A, et al. Surgical treatment of systemic sclerosis--is it justified to offer peripheral sympathectomy earlier in the disease process? Microsurgery. 2015 Sep;35(6):441-6. http://www.ncbi.nlm.nih.gov/pubmed/25585522?tool=bestpractice.com
lifestyle measures
Treatment recommended for ALL patients in selected patient group
Lifestyle measures should also be considered alongside treatment in people with secondary RP who have progressed to digital ulceration. These include keeping warm and avoiding damp: for instance, by wearing gloves or using hand warmers. Patients should be advised to quit smoking and avoid drugs known to exacerbate RP (e.g., beta-blockers, ergotamine, clonidine, cyclosporine, caffeine, cocaine, amphetamines). Avoiding injury to digits and exposure to vibration, as well as minimizing stress, are also recommended. Vasoconstrictor drugs should be discontinued where possible.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23. https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661 http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com [31]Parodis I, Gomez A, Tsoi A, et al. Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. RMD Open. 2023 Aug;9(3):e003297. https://rmdopen.bmj.com/content/9/3/e003297.long http://www.ncbi.nlm.nih.gov/pubmed/37532469?tool=bestpractice.com Patients should also be advised to moisturize the skin around ulcers, avoid contact with cleaning agents, avoid manipulation of ulcers, wear protective gloves, and promote circulation through exercise.[32]Stöcker JK, Schouffoer AA, Spierings J, et al. Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis. Rheumatology (Oxford). 2022 Apr 11;61(4):1476-86. https://academic.oup.com/rheumatology/article/61/4/1476/6321467?login=false http://www.ncbi.nlm.nih.gov/pubmed/34260723?tool=bestpractice.com If dexterity limitations are reported, patients should undergo occupational therapy assessment for aids (e.g., key holders).
treatment of underlying condition
Treatment recommended for ALL patients in selected patient group
Treatment for the underlying condition that has resulted in secondary RP should be instigated after appropriate specialist consultation.
atorvastatin
Treatment recommended for SOME patients in selected patient group
Atorvastatin has been found to decrease new ulcer formation in patients with secondary RP and may be used in patients with past or present digital ulcers, but is not indicated for the prevention of digital ulcers.[35]Hughes M, Ong VH, Anderson ME, et al. Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology (Oxford). 2015 Nov;54(11):2015-24. http://www.ncbi.nlm.nih.gov/pubmed/26116156?tool=bestpractice.com [66]Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol. 2008 Sep;35(9):1801-8. https://www.jrheum.org/content/35/9/1801.long http://www.ncbi.nlm.nih.gov/pubmed/18709692?tool=bestpractice.com
Primary options
atorvastatin: 40 mg orally once daily
analgesia
Treatment recommended for SOME patients in selected patient group
Pain relief is an important component of symptom management. Vasodilators treat the pain of RP if they are effective in reducing the frequency, severity, or duration of attacks. However, analgesics may be required to treat pain from severe or prolonged ischemia or complications such as gangrene or digital ulcers.
Local pain management algorithms should be followed, and treatment should be tailored to medical history and any relative/absolute contraindications. Simple analgesics such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) may be sufficient. Short- or long-acting opioids may be required. Digital ulcers may be very painful, and codeine or oxycodone may be indicated. Rarely, transdermal fentanyl is used if other opioids are not effective or not tolerated, typically for patients with gangrene or osteomyelitis. Local palmar and/or digital sympathectomy is a last-line option.
Primary options
acetaminophen: 325-1000 mg orally/rectally every 4-6 hours when required, maximum 4000 mg/day
OR
ibuprofen: 300-400 mg orally every 4-6 hours when required, maximum 2400 mg/day
OR
naproxen: 250-500 mg orally twice daily when required, maximum 1250 mg/day
OR
diclofenac potassium: 50 mg orally (immediate-release) twice or three times daily when required
OR
diclofenac sodium: 100 mg orally (extended-release) once daily when required
Secondary options
codeine sulfate: 15-60 mg orally every 4-6 hours when required, maximum 360 mg/day
OR
oxycodone: 5-10 mg orally (immediate-release) every 4-6 hours when required; 10 mg orally (extended-release) every 12 hours when required
Tertiary options
fentanyl transdermal: 12.5 micrograms/hour patch applied every 72 hours, increase to 25 micrograms/hour patch applied every 72 hours if required
aspirin
Treatment recommended for SOME patients in selected patient group
Aspirin may be beneficial in helping prevent microthrombi formation.
Primary options
aspirin: 81 mg orally once daily
surgical debridement
Treatment recommended for SOME patients in selected patient group
If there is a large fingertip ulcer, debridement by a surgeon may be necessary to remove necrotic tissue and/or infection and to promote healing.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23. https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661 http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com If gangrene has progressed in spite of treatment, amputation of the digit may be required.
systemic antibiotics
Treatment recommended for SOME patients in selected patient group
Antibiotics should be given when ulcers are infected. Infections are often due to Staphylococcus aureus or Pseudomonas aeruginosa, but can also be caused by Escherichia coli, Enterococcus faecalis, Streptococcus epidermidis, or Bacillus morganii.[73]Giuggioli D, Magnani L, Spinella A, et al. Infections of scleroderma digital ulcers: a single center cohort retrospective study. Dermatol Reports. 2021 Nov 17;13(3):9075. https://www.pagepress.org/journals/index.php/dr/article/view/9075 http://www.ncbi.nlm.nih.gov/pubmed/35003566?tool=bestpractice.com If there is frank purulence, it is advisable to take a swab for culture and sensitivities prior to starting antibiotics, and to tailor treatment based on swab sensitivities and severity of infection. Examples of antibiotic options may include cloxacillin, cephalexin, or erythromycin. However, you should consult your local protocols for guidance.
If infection is not resolved after 7 days of treatment (e.g., continued discolored purulence), treat for another 3 to 7 days.
If osteomyelitis is suspected, seek specialist advice from a microbiologist. See Osteomyelitis.
Primary options
cephalexin: 500 mg orally four times daily
Secondary options
erythromycin base: 250-500 mg orally four times daily
topical antibacterial ointment
Treatment recommended for SOME patients in selected patient group
Topical antibacterials can be used if there is no evidence of a serious infection, but these may be working as a barrier and lubricant more than an antibacterial.
Primary options
mupirocin topical: apply ointment thinly to ulcer twice daily
OR
bacitracin/polymyxin B topical: apply ointment thinly to ulcer twice daily
bosentan
Treatment recommended for SOME patients in selected patient group
Can be used to help prevent formation of systemic sclerosis-related digital ulcers.[67]Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004 Dec;50(12):3985-93. http://onlinelibrary.wiley.com/doi/10.1002/art.20676/full http://www.ncbi.nlm.nih.gov/pubmed/15593188?tool=bestpractice.com [68]Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011 Jan;70(1):32-8. https://ard.bmj.com/content/70/1/32.long http://www.ncbi.nlm.nih.gov/pubmed/20805294?tool=bestpractice.com [69]Hosseinbalam M, Nouri R, Farajzadegan Z, et al. Effectiveness of bosentan in the treatment of systemic sclerosis-related digital ulcers: systematic review and meta-analysis. J Res Med Sci. 2023 Jan 31:28:3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039099 http://www.ncbi.nlm.nih.gov/pubmed/36974107?tool=bestpractice.com It has been found to reduce the incidence of new ulcers by 30% to 50%.[68]Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011 Jan;70(1):32-8. https://ard.bmj.com/content/70/1/32.long http://www.ncbi.nlm.nih.gov/pubmed/20805294?tool=bestpractice.com However, it is not superior to usual care in healing current ulcers.
Liver function tests need to be checked monthly during treatment, and the duration of treatment required for prevention of digital ulcers is unknown but may be indefinitely.[67]Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004 Dec;50(12):3985-93. http://onlinelibrary.wiley.com/doi/10.1002/art.20676/full http://www.ncbi.nlm.nih.gov/pubmed/15593188?tool=bestpractice.com [70]Varga J. New hope for systemic sclerosis patients with digital ulcers. Curr Rheumatol Rep. 2005 Apr;7(2):127-8. http://www.ncbi.nlm.nih.gov/pubmed/15760591?tool=bestpractice.com [71]Seibold JR, Matucci-Cerinic M, Denton CP, et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. Ann Rheum Dis. 2006;65(suppl II):90. This use is off-label in the US.
Primary options
bosentan: 62.5 mg orally twice daily for 1 month, followed by 125 mg orally twice daily thereafter
More bosentanRestricted distribution in US.
primary or mild secondary RP
lifestyle measures
Many patients with RP do not require treatment unless symptoms become severe.
Nonpharmacologic interventions should be considered first in primary or mild secondary RP and mainly include preventative measures and avoidance of triggers. These include keeping warm and avoiding damp: for instance, by wearing gloves or using hand warmers. Advice should be given about quitting smoking, moisturizing dry skin, and avoiding drugs known to exacerbate RP (e.g., beta-blockers, ergotamine, clonidine, cyclosporine, caffeine, cocaine, amphetamines). Avoiding injury to digits and exposure to vibration, as well as minimizing stress, are also recommended. Vasoconstrictor drugs should be discontinued where possible.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23. https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661 http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com [31]Parodis I, Gomez A, Tsoi A, et al. Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. RMD Open. 2023 Aug;9(3):e003297. https://rmdopen.bmj.com/content/9/3/e003297.long http://www.ncbi.nlm.nih.gov/pubmed/37532469?tool=bestpractice.com
analgesia
Treatment recommended for SOME patients in selected patient group
Pain relief is an important component of symptom management. Vasodilators treat the pain of RP if they are effective in reducing the frequency, severity, or duration of attacks. However, additional analgesics may be required to treat pain.
Local pain management algorithms should be followed, and treatment should be tailored to medical history and any relative/absolute contraindications. Simple analgesics such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) may be sufficient. Short- or long-acting opioids may be required. Digital ulcers may be very painful, and codeine or oxycodone may be indicated. Rarely, transdermal fentanyl is used if other opioids are not effective or not tolerated, typically for patients with gangrene or osteomyelitis. Local palmar and/or digital sympathectomy is a last-line option.
Primary options
acetaminophen: 325-1000 mg orally/rectally every 4-6 hours when required, maximum 4000 mg/day
OR
ibuprofen: 300-400 mg orally every 4-6 hours when required, maximum 2400 mg/day
OR
naproxen: 250-500 mg orally twice daily when required, maximum 1250 mg/day
OR
diclofenac potassium: 50 mg orally (immediate-release) twice or three times daily when required
OR
diclofenac sodium: 100 mg orally (extended-release) once daily when required
Secondary options
codeine sulfate: 15-60 mg orally every 4-6 hours when required, maximum 360 mg/day
OR
oxycodone: 5-10 mg orally (immediate-release) every 4-6 hours when required; 10 mg orally (extended-release) every 12 hours when required
Tertiary options
fentanyl transdermal: 12.5 micrograms/hour patch applied every 72 hours, increase to 25 micrograms/hour patch applied every 72 hours if required
complementary and alternative therapies
Treatment recommended for SOME patients in selected patient group
Several alternative therapies or supplements have been claimed to help improve RP; however, these lack sufficient evidence and rely on patient testimonials. Complementary and alternative therapies that have been investigated in randomized controlled trials include evening primrose oil, omega-3 fatty acids, Ginkgo biloba, biofeedback, acupuncture, and low-level laser therapy.[77]DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's: a double-blind, controlled, prospective study. Am J Med. 1989 Feb;86(2):158-64. http://www.ncbi.nlm.nih.gov/pubmed/2536517?tool=bestpractice.com [78]Muir AH, Robb R, McLaren M, et al. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo controlled trial. Vasc Med. 2002;7(4):265-7. https://journals.sagepub.com/doi/10.1191/1358863x02vm455oa http://www.ncbi.nlm.nih.gov/pubmed/12710841?tool=bestpractice.com [79]Bredie SJ, Jong MC. No significant effect of ginkgo biloba special extract EGb 761 in the treatment of primary Raynaud phenomenon: a randomized controlled trial. J Cardiovasc Pharmacol. 2012 Mar;59(3):215-21. http://www.ncbi.nlm.nih.gov/pubmed/22030896?tool=bestpractice.com [80]Appiah R, Hiller S, Caspary L, et al. Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture. J Intern Med. 1997 Feb;241(2):119-24. https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2796.1997.91105000.x http://www.ncbi.nlm.nih.gov/pubmed/9077368?tool=bestpractice.com [81]Al-Awami M, Schillinger M, Maca T, et al. Low-level laser therapy treatment of primary and secondary Raynaud's phenomenon. Vasa. 2001 Nov;30(4):281-4. http://www.ncbi.nlm.nih.gov/pubmed/11771213?tool=bestpractice.com [82]Belch JJ, Shaw B, O'Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. Thromb Haemost. 1985 Aug 30;54(2):490-4. http://www.ncbi.nlm.nih.gov/pubmed/4082084?tool=bestpractice.com A review and meta-analysis of complementary and alternative medicines in the treatment of RP found most trials were negative, of poor quality, and done prior to 1990.[83]Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis. Rheumatology (Oxford). 2009 Jul;48(7):791-5. https://academic.oup.com/rheumatology/article/48/7/791/1788881?login=false http://www.ncbi.nlm.nih.gov/pubmed/19433434?tool=bestpractice.com However, given the limited risks associated with these treatments, using them as an adjunctive therapy may be considered for patients at any stage of RP severity, but patients should be informed on their lack of shown efficacy.
One study involving patients with RP who were deficient in vitamin D showed improvements on the visual analog scale with use of oral vitamin D3 supplementation compared with placebo supplementation.[84]Hélou J, Moutran R, Maatouk I, et al. Raynaud's phenomenon and vitamin D. Rheumatol Int. 2013 Mar;33(3):751-5. http://www.ncbi.nlm.nih.gov/pubmed/22580932?tool=bestpractice.com
The effects of ceramic or silver-lined gloves in RP have also been investigated. One study reported improvement in pain and dexterity in patients using ceramic-lined gloves for 3 months compared with cotton gloves, whereas a 2022 study investigating silver-lined gloves found no improvement compared with normal gloves.[85]Ko GD, Berbrayer D. Effect of ceramic-impregnated "thermoflow" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study. Altern Med Rev. 2002 Aug;7(4):328-35. http://www.ncbi.nlm.nih.gov/pubmed/12197784?tool=bestpractice.com [86]Liem SIE, Hoekstra EM, Bonte-Mineur F, et al. The effect of silver fibre gloves on Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial. Rheumatology (Oxford). 2023 Feb 6;62(si):74-81. https://academic.oup.com/rheumatology/article/62/SI/SI74/6571140?login=false http://www.ncbi.nlm.nih.gov/pubmed/35441683?tool=bestpractice.com
calcium-channel blocker
Calcium-channel blockers have been shown to decrease the frequency/severity of RP attacks, often by 30%.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23.
https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661
http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com
[33]Huisstede BM, Hoogvliet P, Paulis WD, et al. Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review. Arch Phys Med Rehabil. 2011 Jul;92(7):1166-80.
http://www.ncbi.nlm.nih.gov/pubmed/21704799?tool=bestpractice.com
[34]Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford). 2005 Feb;44(2):145-50.
https://academic.oup.com/rheumatology/article/44/2/145/2899216?login=false
http://www.ncbi.nlm.nih.gov/pubmed/15546967?tool=bestpractice.com
[35]Hughes M, Ong VH, Anderson ME, et al. Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology (Oxford). 2015 Nov;54(11):2015-24.
http://www.ncbi.nlm.nih.gov/pubmed/26116156?tool=bestpractice.com
[ ]
How do calcium channel blockers compare with placebo in people with Raynaud's phenomenon?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.2065/fullShow me the answer
[
]
In people with primary Raynaud's phenomenon, how do calcium channel blockers affect outcomes?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.1242/fullShow me the answer Meta-analyses have demonstrated that dihydropyridine calcium-channel blockers are effective in primary and secondary RP. Recommended agents include nifedipine, nicardipine, and less well-studied agents, including amlodipine or felodipine.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23.
https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661
http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com
[35]Hughes M, Ong VH, Anderson ME, et al. Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology (Oxford). 2015 Nov;54(11):2015-24.
http://www.ncbi.nlm.nih.gov/pubmed/26116156?tool=bestpractice.com
[36]Ennis H, Hughes M, Anderson ME, et al. Calcium channel blockers for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2016 Feb 25;2(2):CD002069.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002069.pub5/full
http://www.ncbi.nlm.nih.gov/pubmed/26914257?tool=bestpractice.com
[37]Rirash F, Tingey PC, Harding SE, et al. Calcium channel blockers for primary and secondary Raynaud's phenomenon. Cochrane Database Syst Rev. 2017 Dec 13;12:CD000467.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000467.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/29237099?tool=bestpractice.com
[38]La Civita L, Pitaro N, Rossi M, et al. Amlodipine in the treatment of Raynaud's phenomenon. Br J Rheumatol. 1993 Jun;32(6):524-5.
http://www.ncbi.nlm.nih.gov/pubmed/8508292?tool=bestpractice.com
Nondihydropyridine classes of calcium-channel blockers (e.g., diltiazem) can be offered if dihydropyridine calcium-channel blockers cannot be used or are ineffective.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23. https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661 http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com [36]Ennis H, Hughes M, Anderson ME, et al. Calcium channel blockers for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2016 Feb 25;2(2):CD002069. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002069.pub5/full http://www.ncbi.nlm.nih.gov/pubmed/26914257?tool=bestpractice.com [39]Rhedda A, McCans J, Willan AR, et al. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon. J Rheumatol. 1985 Aug;12(4):724-7. http://www.ncbi.nlm.nih.gov/pubmed/3903157?tool=bestpractice.com
Calcium-channel blockers may not be effective in all patients and may have adverse effects such as hypotension, lightheadedness, flushing, and ankle puffiness. Short-acting calcium-channel blockers may cause orthostatic hypotension, and many people with RP are young and have normal-to-low blood pressure. If the short-acting calcium-channel blocker is tolerated but not effective, then the dose can be increased.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23. https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661 http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com
Calcium-channel blockers can be prescribed on an "as required" basis, such as in cold weather.
Primary options
nifedipine: 10 mg orally (immediate-release) three times daily, titrate according to response, maximum 180 mg/day; 30-60 mg orally (extended-release) once daily
OR
nicardipine: 20 mg orally three times daily, maximum 120 mg/day
Secondary options
felodipine: 2.5 mg orally once daily, titrate according to response, maximum 10 mg/day
OR
amlodipine: 2.5 mg orally once daily, titrate according to response, maximum 10 mg/day
Tertiary options
diltiazem: 30 mg orally (immediate-release) four times daily, maximum 360 mg/day
lifestyle measures
Treatment recommended for ALL patients in selected patient group
Lifestyle measures should also be considered alongside treatment in people with primary or mild secondary RP, and mainly include preventative measures and avoidance of triggers. These include keeping warm and avoiding damp: for instance, by wearing gloves or using hand warmers. Advice should be given about quitting smoking, moisturizing dry skin, and avoiding drugs known to exacerbate RP (e.g., beta-blockers, ergotamine, clonidine, cyclosporine, caffeine, cocaine, amphetamines). Avoiding injury to digits and exposure to vibration, as well as minimizing stress, are also recommended. Vasoconstrictor drugs should be discontinued where possible.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23. https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661 http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com [31]Parodis I, Gomez A, Tsoi A, et al. Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. RMD Open. 2023 Aug;9(3):e003297. https://rmdopen.bmj.com/content/9/3/e003297.long http://www.ncbi.nlm.nih.gov/pubmed/37532469?tool=bestpractice.com
analgesia
Treatment recommended for SOME patients in selected patient group
Pain relief is an important component of symptom management. Vasodilators treat the pain of RP if they are effective in reducing the frequency, severity, or duration of attacks. However, additional analgesics may be required to treat pain.
Local pain management algorithms should be followed, and treatment should be tailored to medical history and any relative/absolute contraindications. Simple analgesics such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) may be sufficient. Short- or long-acting opioids may be required. Digital ulcers may be very painful, and codeine or oxycodone may be indicated. Rarely, transdermal fentanyl is used if other opioids are not effective or not tolerated, typically for patients with gangrene or osteomyelitis. Local palmar and/or digital sympathectomy is a last-line option.
Primary options
acetaminophen: 325-1000 mg orally/rectally every 4-6 hours when required, maximum 4000 mg/day
OR
ibuprofen: 300-400 mg orally every 4-6 hours when required, maximum 2400 mg/day
OR
naproxen: 250-500 mg orally twice daily when required, maximum 1250 mg/day
OR
diclofenac potassium: 50 mg orally (immediate-release) twice or three times daily when required
OR
diclofenac sodium: 100 mg orally (extended-release) once daily when required
Secondary options
codeine sulfate: 15-60 mg orally every 4-6 hours when required, maximum 360 mg/day
OR
oxycodone: 5-10 mg orally (immediate-release) every 4-6 hours when required; 10 mg orally (extended-release) every 12 hours when required
Tertiary options
fentanyl transdermal: 12.5 micrograms/hour patch applied every 72 hours, increase to 25 micrograms/hour patch applied every 72 hours if required
complementary and alternative therapies
Treatment recommended for SOME patients in selected patient group
Several alternative therapies or supplements have been claimed to help improve RP; however, these lack sufficient evidence and rely on patient testimonials. Complementary and alternative therapies that have been investigated in randomized controlled trials include evening primrose oil, omega-3 fatty acids, Ginkgo biloba, biofeedback, acupuncture, and low-level laser therapy.[77]DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's: a double-blind, controlled, prospective study. Am J Med. 1989 Feb;86(2):158-64. http://www.ncbi.nlm.nih.gov/pubmed/2536517?tool=bestpractice.com [78]Muir AH, Robb R, McLaren M, et al. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo controlled trial. Vasc Med. 2002;7(4):265-7. https://journals.sagepub.com/doi/10.1191/1358863x02vm455oa http://www.ncbi.nlm.nih.gov/pubmed/12710841?tool=bestpractice.com [79]Bredie SJ, Jong MC. No significant effect of ginkgo biloba special extract EGb 761 in the treatment of primary Raynaud phenomenon: a randomized controlled trial. J Cardiovasc Pharmacol. 2012 Mar;59(3):215-21. http://www.ncbi.nlm.nih.gov/pubmed/22030896?tool=bestpractice.com [80]Appiah R, Hiller S, Caspary L, et al. Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture. J Intern Med. 1997 Feb;241(2):119-24. https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2796.1997.91105000.x http://www.ncbi.nlm.nih.gov/pubmed/9077368?tool=bestpractice.com [81]Al-Awami M, Schillinger M, Maca T, et al. Low-level laser therapy treatment of primary and secondary Raynaud's phenomenon. Vasa. 2001 Nov;30(4):281-4. http://www.ncbi.nlm.nih.gov/pubmed/11771213?tool=bestpractice.com [82]Belch JJ, Shaw B, O'Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. Thromb Haemost. 1985 Aug 30;54(2):490-4. http://www.ncbi.nlm.nih.gov/pubmed/4082084?tool=bestpractice.com A review and meta-analysis of complementary and alternative medicines in the treatment of RP found most trials were negative, of poor quality, and done prior to 1990.[83]Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis. Rheumatology (Oxford). 2009 Jul;48(7):791-5. https://academic.oup.com/rheumatology/article/48/7/791/1788881?login=false http://www.ncbi.nlm.nih.gov/pubmed/19433434?tool=bestpractice.com However, given the limited risks associated with these treatments, using them as an adjunctive therapy may be considered for patients at any stage of RP severity, but patients should be informed on their lack of shown efficacy.
One study involving patients with RP who were deficient in vitamin D showed improvements on the visual analog scale with use of oral vitamin D3 supplementation compared with placebo supplementation.[84]Hélou J, Moutran R, Maatouk I, et al. Raynaud's phenomenon and vitamin D. Rheumatol Int. 2013 Mar;33(3):751-5. http://www.ncbi.nlm.nih.gov/pubmed/22580932?tool=bestpractice.com
The effects of ceramic or silver-lined gloves in RP have also been investigated. One study reported improvement in pain and dexterity in patients using ceramic-lined gloves for 3 months compared with cotton gloves, whereas a 2022 study investigating silver-lined gloves found no improvement compared with normal gloves.[85]Ko GD, Berbrayer D. Effect of ceramic-impregnated "thermoflow" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study. Altern Med Rev. 2002 Aug;7(4):328-35. http://www.ncbi.nlm.nih.gov/pubmed/12197784?tool=bestpractice.com [86]Liem SIE, Hoekstra EM, Bonte-Mineur F, et al. The effect of silver fibre gloves on Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial. Rheumatology (Oxford). 2023 Feb 6;62(si):74-81. https://academic.oup.com/rheumatology/article/62/SI/SI74/6571140?login=false http://www.ncbi.nlm.nih.gov/pubmed/35441683?tool=bestpractice.com
ACE inhibitor or angiotensin-II receptor antagonist
ACE inhibitors (e.g., captopril) have also been used as alternatives to calcium-channel blockers but have shown conflicting results.[44]Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud's phenomenon. Ann Pharmacother. 2006 Nov;40(11):1998-2002. http://www.ncbi.nlm.nih.gov/pubmed/17003081?tool=bestpractice.com A 2021 systematic review found that captopril and enalapril may increase the frequency of attacks in primary RP.[40]Su KY, Sharma M, Kim HJ, et al. Vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2021 May 17;5(5):CD006687. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006687.pub4/full http://www.ncbi.nlm.nih.gov/pubmed/33998674?tool=bestpractice.com A randomized controlled trial found that treatment with quinapril showed no improvement in secondary RP attacks.[54]Gliddon AE, Doré CJ, Black CM, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum. 2007 Nov;56(11):3837-46. http://onlinelibrary.wiley.com/doi/10.1002/art.22965/full http://www.ncbi.nlm.nih.gov/pubmed/17968938?tool=bestpractice.com
Two studies have shown a reduction in RP attacks in patients treated with the angiotensin-II receptor antagonist losartan, with one study showing improvement in RP symptoms compared with nifedipine.[42]Pancera P, Sansone S, Secchi S, et al. The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon. J Intern Med. 1997 Nov;242(5):373-6. https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2796.1997.00219.x http://www.ncbi.nlm.nih.gov/pubmed/9408065?tool=bestpractice.com [43]Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 1999 Dec;42(12):2646-55. https://onlinelibrary.wiley.com/doi/10.1002/1529-0131(199912)42:12%3C2646::AID-ANR21%3E3.0.CO;2-T http://www.ncbi.nlm.nih.gov/pubmed/10616013?tool=bestpractice.com [44]Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud's phenomenon. Ann Pharmacother. 2006 Nov;40(11):1998-2002. http://www.ncbi.nlm.nih.gov/pubmed/17003081?tool=bestpractice.com
Primary options
losartan: 25-100 mg orally once daily
OR
captopril: 25-150 mg orally three times daily
lifestyle measures
Treatment recommended for ALL patients in selected patient group
Lifestyle measures should also be considered alongside treatment in people with primary or mild secondary RP, and mainly include preventative measures and avoidance of triggers. These include keeping warm and avoiding damp: for instance, by wearing gloves or using hand warmers. Advice should be given about quitting smoking, moisturizing dry skin, and avoiding drugs known to exacerbate RP (e.g., beta-blockers, ergotamine, clonidine, cyclosporine, caffeine, cocaine, amphetamines). Avoiding injury to digits and exposure to vibration, as well as minimizing stress, are also recommended. Vasoconstrictor drugs should be discontinued where possible.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23. https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661 http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com [31]Parodis I, Gomez A, Tsoi A, et al. Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. RMD Open. 2023 Aug;9(3):e003297. https://rmdopen.bmj.com/content/9/3/e003297.long http://www.ncbi.nlm.nih.gov/pubmed/37532469?tool=bestpractice.com
analgesia
Treatment recommended for SOME patients in selected patient group
Pain relief is an important component of symptom management. Vasodilators treat the pain of RP if they are effective in reducing the frequency, severity, or duration of attacks. However, additional analgesics may be required to treat pain.
Local pain management algorithms should be followed, and treatment should be tailored to medical history and any relative/absolute contraindications. Simple analgesics such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) may be sufficient. Short- or long-acting opioids may be required. Digital ulcers may be very painful, and codeine or oxycodone may be indicated. Rarely, transdermal fentanyl is used if other opioids are not effective or not tolerated, typically for patients with gangrene or osteomyelitis. Local palmar and/or digital sympathectomy is a last-line option.
Primary options
acetaminophen: 325-1000 mg orally/rectally every 4-6 hours when required, maximum 4000 mg/day
OR
ibuprofen: 300-400 mg orally every 4-6 hours when required, maximum 2400 mg/day
OR
naproxen: 250-500 mg orally twice daily when required, maximum 1250 mg/day
OR
diclofenac potassium: 50 mg orally (immediate-release) twice or three times daily when required
OR
diclofenac sodium: 100 mg orally (extended-release) once daily when required
Secondary options
codeine sulfate: 15-60 mg orally every 4-6 hours when required, maximum 360 mg/day
OR
oxycodone: 5-10 mg orally (immediate-release) every 4-6 hours when required; 10 mg orally (extended-release) every 12 hours when required
Tertiary options
fentanyl transdermal: 12.5 micrograms/hour patch applied every 72 hours, increase to 25 micrograms/hour patch applied every 72 hours if required
complementary and alternative therapies
Treatment recommended for SOME patients in selected patient group
Several alternative therapies or supplements have been claimed to help improve RP; however, these lack sufficient evidence and rely on patient testimonials. Complementary and alternative therapies that have been investigated in randomized controlled trials include evening primrose oil, omega-3 fatty acids, Ginkgo biloba, biofeedback, acupuncture, and low-level laser therapy.[77]DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's: a double-blind, controlled, prospective study. Am J Med. 1989 Feb;86(2):158-64. http://www.ncbi.nlm.nih.gov/pubmed/2536517?tool=bestpractice.com [78]Muir AH, Robb R, McLaren M, et al. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo controlled trial. Vasc Med. 2002;7(4):265-7. https://journals.sagepub.com/doi/10.1191/1358863x02vm455oa http://www.ncbi.nlm.nih.gov/pubmed/12710841?tool=bestpractice.com [79]Bredie SJ, Jong MC. No significant effect of ginkgo biloba special extract EGb 761 in the treatment of primary Raynaud phenomenon: a randomized controlled trial. J Cardiovasc Pharmacol. 2012 Mar;59(3):215-21. http://www.ncbi.nlm.nih.gov/pubmed/22030896?tool=bestpractice.com [80]Appiah R, Hiller S, Caspary L, et al. Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture. J Intern Med. 1997 Feb;241(2):119-24. https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2796.1997.91105000.x http://www.ncbi.nlm.nih.gov/pubmed/9077368?tool=bestpractice.com [81]Al-Awami M, Schillinger M, Maca T, et al. Low-level laser therapy treatment of primary and secondary Raynaud's phenomenon. Vasa. 2001 Nov;30(4):281-4. http://www.ncbi.nlm.nih.gov/pubmed/11771213?tool=bestpractice.com [82]Belch JJ, Shaw B, O'Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. Thromb Haemost. 1985 Aug 30;54(2):490-4. http://www.ncbi.nlm.nih.gov/pubmed/4082084?tool=bestpractice.com A review and meta-analysis of complementary and alternative medicines in the treatment of RP found most trials were negative, of poor quality, and done prior to 1990.[83]Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis. Rheumatology (Oxford). 2009 Jul;48(7):791-5. https://academic.oup.com/rheumatology/article/48/7/791/1788881?login=false http://www.ncbi.nlm.nih.gov/pubmed/19433434?tool=bestpractice.com However, given the limited risks associated with these treatments, using them as an adjunctive therapy may be considered for patients at any stage of RP severity, but patients should be informed on their lack of shown efficacy.
One study involving patients with RP who were deficient in vitamin D showed improvements on the visual analog scale with use of oral vitamin D3 supplementation compared with placebo supplementation.[84]Hélou J, Moutran R, Maatouk I, et al. Raynaud's phenomenon and vitamin D. Rheumatol Int. 2013 Mar;33(3):751-5. http://www.ncbi.nlm.nih.gov/pubmed/22580932?tool=bestpractice.com
The effects of ceramic or silver-lined gloves in RP have also been investigated. One study reported improvement in pain and dexterity in patients using ceramic-lined gloves for 3 months compared with cotton gloves, whereas a 2022 study investigating silver-lined gloves found no improvement compared with normal gloves.[85]Ko GD, Berbrayer D. Effect of ceramic-impregnated "thermoflow" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study. Altern Med Rev. 2002 Aug;7(4):328-35. http://www.ncbi.nlm.nih.gov/pubmed/12197784?tool=bestpractice.com [86]Liem SIE, Hoekstra EM, Bonte-Mineur F, et al. The effect of silver fibre gloves on Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial. Rheumatology (Oxford). 2023 Feb 6;62(si):74-81. https://academic.oup.com/rheumatology/article/62/SI/SI74/6571140?login=false http://www.ncbi.nlm.nih.gov/pubmed/35441683?tool=bestpractice.com
selective serotonin-reuptake inhibitor
Selective serotonin-reuptake inhibitors (SSRIs) may be used as a third-line option when other drugs have failed or are not tolerated.
The association between SSRIs and RP is controversial. Treatment with the SSRI fluoxetine also showed a decrease in frequency and severity of attacks in one randomized trial.[45]Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford). 2001 Sep;40(9):1038-43. https://academic.oup.com/rheumatology/article/40/9/1038/1787964?login=false http://www.ncbi.nlm.nih.gov/pubmed/11561116?tool=bestpractice.com However, other studies report that SSRIs may exacerbate RP symptoms.[7]Khouri C, Blaise S, Carpentier P, et al. Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers. Br J Clin Pharmacol. 2016 Jul;82(1):6-16. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.12912 http://www.ncbi.nlm.nih.gov/pubmed/26949933?tool=bestpractice.com [46]Khouri C, Gailland T, Lepelley M, et al. Fluoxetine and Raynaud's phenomenon: friend or foe? Br J Clin Pharmacol. 2017 Oct;83(10):2307-9. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.13314 http://www.ncbi.nlm.nih.gov/pubmed/28580711?tool=bestpractice.com
Primary options
fluoxetine: 20-60 mg orally once daily
lifestyle measures
Treatment recommended for ALL patients in selected patient group
Lifestyle measures should also be considered alongside treatment in people with primary or mild secondary RP, and mainly include preventative measures and avoidance of triggers. These include keeping warm and avoiding damp: for instance, by wearing gloves or using hand warmers. Advice should be given about quitting smoking, moisturizing dry skin, and avoiding drugs known to exacerbate RP (e.g., beta-blockers, ergotamine, clonidine, cyclosporine, caffeine, cocaine, amphetamines). Avoiding injury to digits and exposure to vibration, as well as minimizing stress, are also recommended. Vasoconstrictor drugs should be discontinued where possible.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23. https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661 http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com [31]Parodis I, Gomez A, Tsoi A, et al. Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. RMD Open. 2023 Aug;9(3):e003297. https://rmdopen.bmj.com/content/9/3/e003297.long http://www.ncbi.nlm.nih.gov/pubmed/37532469?tool=bestpractice.com
analgesia
Treatment recommended for SOME patients in selected patient group
Pain relief is an important component of symptom management. Vasodilators treat the pain of RP if they are effective in reducing the frequency, severity, or duration of attacks. However, additional analgesics may be required to treat pain.
Local pain management algorithms should be followed, and treatment should be tailored to medical history and any relative/absolute contraindications. Simple analgesics such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) may be sufficient. Short- or long-acting opioids may be required. Digital ulcers may be very painful, and codeine or oxycodone may be indicated. Rarely, transdermal fentanyl is used if other opioids are not effective or not tolerated, typically for patients with gangrene or osteomyelitis. Local palmar and/or digital sympathectomy is a last-line option.
Primary options
acetaminophen: 325-1000 mg orally/rectally every 4-6 hours when required, maximum 4000 mg/day
OR
ibuprofen: 300-400 mg orally every 4-6 hours when required, maximum 2400 mg/day
OR
naproxen: 250-500 mg orally twice daily when required, maximum 1250 mg/day
OR
diclofenac potassium: 50 mg orally (immediate-release) twice or three times daily when required
OR
diclofenac sodium: 100 mg orally (extended-release) once daily when required
Secondary options
codeine sulfate: 15-60 mg orally every 4-6 hours when required, maximum 360 mg/day
OR
oxycodone: 5-10 mg orally (immediate-release) every 4-6 hours when required; 10 mg orally (extended-release) every 12 hours when required
Tertiary options
fentanyl transdermal: 12.5 micrograms/hour patch applied every 72 hours, increase to 25 micrograms/hour patch applied every 72 hours if required
complementary and alternative therapies
Treatment recommended for SOME patients in selected patient group
Several alternative therapies or supplements have been claimed to help improve RP; however, these lack sufficient evidence and rely on patient testimonials. Complementary and alternative therapies that have been investigated in randomized controlled trials include evening primrose oil, omega-3 fatty acids, Ginkgo biloba, biofeedback, acupuncture, and low-level laser therapy.[77]DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's: a double-blind, controlled, prospective study. Am J Med. 1989 Feb;86(2):158-64. http://www.ncbi.nlm.nih.gov/pubmed/2536517?tool=bestpractice.com [78]Muir AH, Robb R, McLaren M, et al. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo controlled trial. Vasc Med. 2002;7(4):265-7. https://journals.sagepub.com/doi/10.1191/1358863x02vm455oa http://www.ncbi.nlm.nih.gov/pubmed/12710841?tool=bestpractice.com [79]Bredie SJ, Jong MC. No significant effect of ginkgo biloba special extract EGb 761 in the treatment of primary Raynaud phenomenon: a randomized controlled trial. J Cardiovasc Pharmacol. 2012 Mar;59(3):215-21. http://www.ncbi.nlm.nih.gov/pubmed/22030896?tool=bestpractice.com [80]Appiah R, Hiller S, Caspary L, et al. Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture. J Intern Med. 1997 Feb;241(2):119-24. https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2796.1997.91105000.x http://www.ncbi.nlm.nih.gov/pubmed/9077368?tool=bestpractice.com [81]Al-Awami M, Schillinger M, Maca T, et al. Low-level laser therapy treatment of primary and secondary Raynaud's phenomenon. Vasa. 2001 Nov;30(4):281-4. http://www.ncbi.nlm.nih.gov/pubmed/11771213?tool=bestpractice.com [82]Belch JJ, Shaw B, O'Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. Thromb Haemost. 1985 Aug 30;54(2):490-4. http://www.ncbi.nlm.nih.gov/pubmed/4082084?tool=bestpractice.com A review and meta-analysis of complementary and alternative medicines in the treatment of RP found most trials were negative, of poor quality, and done prior to 1990.[83]Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis. Rheumatology (Oxford). 2009 Jul;48(7):791-5. https://academic.oup.com/rheumatology/article/48/7/791/1788881?login=false http://www.ncbi.nlm.nih.gov/pubmed/19433434?tool=bestpractice.com However, given the limited risks associated with these treatments, using them as an adjunctive therapy may be considered for patients at any stage of RP severity, but patients should be informed on their lack of shown efficacy.
One study involving patients with RP who were deficient in vitamin D showed improvements on the visual analog scale with use of oral vitamin D3 supplementation compared with placebo supplementation.[84]Hélou J, Moutran R, Maatouk I, et al. Raynaud's phenomenon and vitamin D. Rheumatol Int. 2013 Mar;33(3):751-5. http://www.ncbi.nlm.nih.gov/pubmed/22580932?tool=bestpractice.com
The effects of ceramic or silver-lined gloves in RP have also been investigated. One study reported improvement in pain and dexterity in patients using ceramic-lined gloves for 3 months compared with cotton gloves, whereas a 2022 study investigating silver-lined gloves found no improvement compared with normal gloves.[85]Ko GD, Berbrayer D. Effect of ceramic-impregnated "thermoflow" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study. Altern Med Rev. 2002 Aug;7(4):328-35. http://www.ncbi.nlm.nih.gov/pubmed/12197784?tool=bestpractice.com [86]Liem SIE, Hoekstra EM, Bonte-Mineur F, et al. The effect of silver fibre gloves on Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial. Rheumatology (Oxford). 2023 Feb 6;62(si):74-81. https://academic.oup.com/rheumatology/article/62/SI/SI74/6571140?login=false http://www.ncbi.nlm.nih.gov/pubmed/35441683?tool=bestpractice.com
topical nitrate
Topical nitroglycerin may be used as a third-line option when other drugs have failed or are not tolerated.
Topical nitrates have been shown to be effective in reducing the frequency and severity of attacks, reducing ulcer size, lowering Raynaud’s Condition Score, and improving blood flow in several randomized controlled trials; however, adverse effects such as headaches may limit their use.[47]Teh LS, Manning J, Moore T, et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol. 1995 Jul;34(7):636-41. http://www.ncbi.nlm.nih.gov/pubmed/7670782?tool=bestpractice.com [48]Franks AG Jr. Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. Lancet. 1982 Jan 9;1(8263):76-7. http://www.ncbi.nlm.nih.gov/pubmed/6119495?tool=bestpractice.com [49]Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum. 2009 Mar;60(3):870-7. https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.24351 http://www.ncbi.nlm.nih.gov/pubmed/19248104?tool=bestpractice.com [50]Hummers LK, Dugowson CE, Dechow FJ, et al. A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon. Ann Rheum Dis. 2013 Dec;72(12):1962-7. http://www.ncbi.nlm.nih.gov/pubmed/23268365?tool=bestpractice.com
Primary options
nitroglycerin topical: (2%) apply to the affected area(s) twice daily
lifestyle measures
Treatment recommended for ALL patients in selected patient group
Lifestyle measures should also be considered alongside treatment in people with primary or mild secondary RP, and mainly include preventative measures and avoidance of triggers. These include keeping warm and avoiding damp: for instance, by wearing gloves or using hand warmers. Advice should be given about quitting smoking, moisturizing dry skin, and avoiding drugs known to exacerbate RP (e.g., beta-blockers, ergotamine, clonidine, cyclosporine, caffeine, cocaine, amphetamines). Avoiding injury to digits and exposure to vibration, as well as minimizing stress, are also recommended. Vasoconstrictor drugs should be discontinued where possible.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23. https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661 http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com [31]Parodis I, Gomez A, Tsoi A, et al. Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. RMD Open. 2023 Aug;9(3):e003297. https://rmdopen.bmj.com/content/9/3/e003297.long http://www.ncbi.nlm.nih.gov/pubmed/37532469?tool=bestpractice.com
analgesia
Treatment recommended for SOME patients in selected patient group
Pain relief is an important component of symptom management. Vasodilators treat the pain of RP if they are effective in reducing the frequency, severity, or duration of attacks. However, additional analgesics may be required to treat pain from severe or prolonged ischemia or complications such as gangrene or digital ulcers.
Local pain management algorithms should be followed, and treatment should be tailored to medical history and any relative/absolute contraindications. Simple analgesics such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) may be sufficient. Short- or long-acting opioids may be required. Digital ulcers may be very painful, and codeine or oxycodone may be indicated. Rarely, transdermal fentanyl is used if other opioids are not effective or not tolerated, typically for patients with gangrene or osteomyelitis. Local palmar and/or digital sympathectomy is a last-line option.
Primary options
acetaminophen: 325-1000 mg orally/rectally every 4-6 hours when required, maximum 4000 mg/day
OR
ibuprofen: 300-400 mg orally every 4-6 hours when required, maximum 2400 mg/day
OR
naproxen: 250-500 mg orally twice daily when required, maximum 1250 mg/day
OR
diclofenac potassium: 50 mg orally (immediate-release) twice or three times daily when required
OR
diclofenac sodium: 100 mg orally (extended-release) once daily when required
Secondary options
codeine sulfate: 15-60 mg orally every 4-6 hours when required, maximum 360 mg/day
OR
oxycodone: 5-10 mg orally (immediate-release) every 4-6 hours when required; 10 mg orally (extended-release) every 12 hours when required
Tertiary options
fentanyl transdermal: 12.5 micrograms/hour patch applied every 72 hours, increase to 25 micrograms/hour patch applied every 72 hours if required
complementary and alternative therapies
Treatment recommended for SOME patients in selected patient group
Several alternative therapies or supplements have been claimed to help improve RP; however, these lack sufficient evidence and rely on patient testimonials. Complementary and alternative therapies that have been investigated in randomized controlled trials include evening primrose oil, omega-3 fatty acids, Ginkgo biloba, biofeedback, acupuncture, and low-level laser therapy.[77]DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's: a double-blind, controlled, prospective study. Am J Med. 1989 Feb;86(2):158-64. http://www.ncbi.nlm.nih.gov/pubmed/2536517?tool=bestpractice.com [78]Muir AH, Robb R, McLaren M, et al. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo controlled trial. Vasc Med. 2002;7(4):265-7. https://journals.sagepub.com/doi/10.1191/1358863x02vm455oa http://www.ncbi.nlm.nih.gov/pubmed/12710841?tool=bestpractice.com [79]Bredie SJ, Jong MC. No significant effect of ginkgo biloba special extract EGb 761 in the treatment of primary Raynaud phenomenon: a randomized controlled trial. J Cardiovasc Pharmacol. 2012 Mar;59(3):215-21. http://www.ncbi.nlm.nih.gov/pubmed/22030896?tool=bestpractice.com [80]Appiah R, Hiller S, Caspary L, et al. Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture. J Intern Med. 1997 Feb;241(2):119-24. https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2796.1997.91105000.x http://www.ncbi.nlm.nih.gov/pubmed/9077368?tool=bestpractice.com [81]Al-Awami M, Schillinger M, Maca T, et al. Low-level laser therapy treatment of primary and secondary Raynaud's phenomenon. Vasa. 2001 Nov;30(4):281-4. http://www.ncbi.nlm.nih.gov/pubmed/11771213?tool=bestpractice.com [82]Belch JJ, Shaw B, O'Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. Thromb Haemost. 1985 Aug 30;54(2):490-4. http://www.ncbi.nlm.nih.gov/pubmed/4082084?tool=bestpractice.com A review and meta-analysis of complementary and alternative medicines in the treatment of RP found most trials were negative, of poor quality, and done prior to 1990.[83]Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis. Rheumatology (Oxford). 2009 Jul;48(7):791-5. https://academic.oup.com/rheumatology/article/48/7/791/1788881?login=false http://www.ncbi.nlm.nih.gov/pubmed/19433434?tool=bestpractice.com However, given the limited risks associated with these treatments, using them as an adjunctive therapy may be considered for patients at any stage of RP severity, but patients should be informed on their lack of shown efficacy.
One study involving patients with RP who were deficient in vitamin D showed improvements on the visual analog scale with use of oral vitamin D3 supplementation compared with placebo supplementation.[84]Hélou J, Moutran R, Maatouk I, et al. Raynaud's phenomenon and vitamin D. Rheumatol Int. 2013 Mar;33(3):751-5. http://www.ncbi.nlm.nih.gov/pubmed/22580932?tool=bestpractice.com
The effects of ceramic or silver-lined gloves in RP have also been investigated. One study reported improvement in pain and dexterity in patients using ceramic-lined gloves for 3 months compared with cotton gloves, whereas a 2022 study investigating silver-lined gloves found no improvement compared with normal gloves.[85]Ko GD, Berbrayer D. Effect of ceramic-impregnated "thermoflow" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study. Altern Med Rev. 2002 Aug;7(4):328-35. http://www.ncbi.nlm.nih.gov/pubmed/12197784?tool=bestpractice.com [86]Liem SIE, Hoekstra EM, Bonte-Mineur F, et al. The effect of silver fibre gloves on Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial. Rheumatology (Oxford). 2023 Feb 6;62(si):74-81. https://academic.oup.com/rheumatology/article/62/SI/SI74/6571140?login=false http://www.ncbi.nlm.nih.gov/pubmed/35441683?tool=bestpractice.com
alpha-blocker
Alpha-blockers may be used as a fourth-line option when all other drugs have failed or are not tolerated.
Treatment with the alpha-blocker prazosin has shown modest improvement in RP in three randomized controlled trials; however, adverse effects may be common and no further trials have been conducted since 1986.[51]Pope J, Fenlon D, Thompson A, et al. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;1998(2):CD000956. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7032637 http://www.ncbi.nlm.nih.gov/pubmed/10796398?tool=bestpractice.com [52]Surwit RS, Gilgor RS, Allen LM, et al. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma. Arch Dermatol. 1984 Mar;120(3):329-31. http://www.ncbi.nlm.nih.gov/pubmed/6367665?tool=bestpractice.com [53]Wollersheim H, Thien T, Fennis J, et al. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon. Clin Pharmacol Ther. 1986 Aug;40(2):219-25. http://www.ncbi.nlm.nih.gov/pubmed/3731684?tool=bestpractice.com
Primary options
prazosin: 1 mg orally twice daily
lifestyle measures
Treatment recommended for ALL patients in selected patient group
Lifestyle measures should also be considered alongside treatment in people with primary or mild secondary RP, and mainly include preventative measures and avoidance of triggers. These include keeping warm and avoiding damp: for instance, by wearing gloves or using hand warmers. Advice should be given about quitting smoking, moisturizing dry skin, and avoiding drugs known to exacerbate RP (e.g., beta-blockers, ergotamine, clonidine, cyclosporine, caffeine, cocaine, amphetamines). Avoiding injury to digits and exposure to vibration, as well as minimizing stress, are also recommended. Vasoconstrictor drugs should be discontinued where possible.[4]Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23. https://econtent.hogrefe.com/doi/10.1024/0301-1526/a000661 http://www.ncbi.nlm.nih.gov/pubmed/28895508?tool=bestpractice.com [31]Parodis I, Gomez A, Tsoi A, et al. Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. RMD Open. 2023 Aug;9(3):e003297. https://rmdopen.bmj.com/content/9/3/e003297.long http://www.ncbi.nlm.nih.gov/pubmed/37532469?tool=bestpractice.com
analgesia
Treatment recommended for SOME patients in selected patient group
Pain relief is an important component of symptom management. Vasodilators treat the pain of RP if they are effective in reducing the frequency, severity, or duration of attacks. However, additional analgesics may be required to treat pain.
Local pain management algorithms should be followed, and treatment should be tailored to medical history and any relative/absolute contraindications. Simple analgesics such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) may be sufficient. Short- or long-acting opioids may be required. Digital ulcers may be very painful, and codeine or oxycodone may be indicated. Rarely, transdermal fentanyl is used if other opioids are not effective or not tolerated, typically for patients with gangrene or osteomyelitis. Local palmar and/or digital sympathectomy is a last-line option.
Primary options
acetaminophen: 325-1000 mg orally/rectally every 4-6 hours when required, maximum 4000 mg/day
OR
ibuprofen: 300-400 mg orally every 4-6 hours when required, maximum 2400 mg/day
OR
naproxen: 250-500 mg orally twice daily when required, maximum 1250 mg/day
OR
diclofenac potassium: 50 mg orally (immediate-release) twice or three times daily when required
OR
diclofenac sodium: 100 mg orally (extended-release) once daily when required
Secondary options
codeine sulfate: 15-60 mg orally every 4-6 hours when required, maximum 360 mg/day
OR
oxycodone: 5-10 mg orally (immediate-release) every 4-6 hours when required; 10 mg orally (extended-release) every 12 hours when required
Tertiary options
fentanyl transdermal: 12.5 micrograms/hour patch applied every 72 hours, increase to 25 micrograms/hour patch applied every 72 hours if required
complementary and alternative therapies
Treatment recommended for SOME patients in selected patient group
Several alternative therapies or supplements have been claimed to help improve RP; however, these lack sufficient evidence and rely on patient testimonials. Complementary and alternative therapies that have been investigated in randomized controlled trials include evening primrose oil, omega-3 fatty acids, Ginkgo biloba, biofeedback, acupuncture, and low-level laser therapy.[77]DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's: a double-blind, controlled, prospective study. Am J Med. 1989 Feb;86(2):158-64. http://www.ncbi.nlm.nih.gov/pubmed/2536517?tool=bestpractice.com [78]Muir AH, Robb R, McLaren M, et al. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo controlled trial. Vasc Med. 2002;7(4):265-7. https://journals.sagepub.com/doi/10.1191/1358863x02vm455oa http://www.ncbi.nlm.nih.gov/pubmed/12710841?tool=bestpractice.com [79]Bredie SJ, Jong MC. No significant effect of ginkgo biloba special extract EGb 761 in the treatment of primary Raynaud phenomenon: a randomized controlled trial. J Cardiovasc Pharmacol. 2012 Mar;59(3):215-21. http://www.ncbi.nlm.nih.gov/pubmed/22030896?tool=bestpractice.com [80]Appiah R, Hiller S, Caspary L, et al. Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture. J Intern Med. 1997 Feb;241(2):119-24. https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2796.1997.91105000.x http://www.ncbi.nlm.nih.gov/pubmed/9077368?tool=bestpractice.com [81]Al-Awami M, Schillinger M, Maca T, et al. Low-level laser therapy treatment of primary and secondary Raynaud's phenomenon. Vasa. 2001 Nov;30(4):281-4. http://www.ncbi.nlm.nih.gov/pubmed/11771213?tool=bestpractice.com [82]Belch JJ, Shaw B, O'Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. Thromb Haemost. 1985 Aug 30;54(2):490-4. http://www.ncbi.nlm.nih.gov/pubmed/4082084?tool=bestpractice.com A review and meta-analysis of complementary and alternative medicines in the treatment of RP found most trials were negative, of poor quality, and done prior to 1990.[83]Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis. Rheumatology (Oxford). 2009 Jul;48(7):791-5. https://academic.oup.com/rheumatology/article/48/7/791/1788881?login=false http://www.ncbi.nlm.nih.gov/pubmed/19433434?tool=bestpractice.com However, given the limited risks associated with these treatments, using them as an adjunctive therapy may be considered for patients at any stage of RP severity, but patients should be informed on their lack of shown efficacy.
One study involving patients with RP who were deficient in vitamin D showed improvements on the visual analog scale with use of oral vitamin D3 supplementation compared with placebo supplementation.[84]Hélou J, Moutran R, Maatouk I, et al. Raynaud's phenomenon and vitamin D. Rheumatol Int. 2013 Mar;33(3):751-5. http://www.ncbi.nlm.nih.gov/pubmed/22580932?tool=bestpractice.com
The effects of ceramic or silver-lined gloves in RP have also been investigated. One study reported improvement in pain and dexterity in patients using ceramic-lined gloves for 3 months compared with cotton gloves, whereas a 2022 study investigating silver-lined gloves found no improvement compared with normal gloves.[85]Ko GD, Berbrayer D. Effect of ceramic-impregnated "thermoflow" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study. Altern Med Rev. 2002 Aug;7(4):328-35. http://www.ncbi.nlm.nih.gov/pubmed/12197784?tool=bestpractice.com [86]Liem SIE, Hoekstra EM, Bonte-Mineur F, et al. The effect of silver fibre gloves on Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial. Rheumatology (Oxford). 2023 Feb 6;62(si):74-81. https://academic.oup.com/rheumatology/article/62/SI/SI74/6571140?login=false http://www.ncbi.nlm.nih.gov/pubmed/35441683?tool=bestpractice.com
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer